Reaction
Hypertrophic Cardiomyopathy reporting signals
As of the last recalculation, Hypertrophic Cardiomyopathy appears in 1,524 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is AGALSIDASE BETA (PRR 28.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Agalsidase Beta | 19 | 28.4 | 28.5 |
| Sirolimus | 22 | 22.6 | 22.6 |
| Desloratadine | 16 | 20.6 | 20.6 |
| Tacrolimus Ointment 0.1% | 152 | 18.4 | 18.4 |
| Tacrolimus Extended-Release Capsules | 152 | 18.4 | 18.4 |
| Tacrolimus | 160 | 15.5 | 15.5 |
| Phenobarbital | 16 | 15.2 | 15.2 |
| Midazolam | 24 | 13.2 | 13.2 |
| Midazolam Hydrochloride | 24 | 12.4 | 12.4 |
| Phenytoin | 18 | 11.9 | 11.9 |
| Valproic Acid | 27 | 11.9 | 11.9 |
| Labetalol | 11 | 11.3 | 11.4 |
| Brivaracetam | 7 | 10.7 | 10.7 |
| Piperacillin Sodium,Tazobactam Sodium | 20 | 10.4 | 10.4 |
| Bupivacaine | 7 | 10.3 | 10.3 |
| Amiodarone Hydrochloride | 8 | 9.8 | 9.8 |
| Ado-Trastuzumab Emtansine | 6 | 9.8 | 9.8 |
| Amikacin | 11 | 8.9 | 8.9 |
| Tafamidis | 6 | 7.0 | 7.0 |
| Ranibizumab | 11 | 5.7 | 5.7 |
| Somatropin | 30 | 5.7 | 5.7 |
| Lapatinib | 6 | 5.3 | 5.3 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 3.7 | 3.7 |